When EF>60 percent, the SGLT2 inhibitor ertugliflozin is unable to prevent HF hospitalization, according to VERTIS CV analyses.

Published Date: 27 Oct 2023

USA: Post-hoc analyses of the VERTIS CV trial failed to show the ability of SGLT2 inhibitor ertugliflozin (Steglatro) to reduce hospitalization for.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

GuCS Future Focus: Future Focus from the Genitourinary Cancers Symposium

2.

The main subject is associated with suicide in the United States.

3.

Alkem introduces cetuximab under the trade name Cetuxa in India.

4.

Firefighters who eat better can combat cancer.

5.

How scientists are hacking bacteria to treat cancer, self-destruct, then vanish without a trace


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot